Early access
Sign in
Not yet taking people in Hong KongPhase 1

Tests probiotic bacteria for blood pressure in middle-aged adults with hypertension

Tests Bifidobacterium probiotics in untreated middle-aged adults with high blood pressure.

Key facts

Who runs it
The University of Hong Kong
Where
Hong Kong, Hong KongSee the site
Trial code
Registry title
The Effects of Bifidobacterium-based Probiotics in Reducing Blood Pressure in Middle-aged Chinese With Hypertension
Status
Not yet recruiting
Phase
Phase 1
People taking part
30 people, planned
Started
Nov 2026
Expected to end
Nov 2027
Type of study
Interventional
Treatments tested
  • Bifidobacterium probiotics supplementation
Record updated
31 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for middle-aged Chinese adults living in Hong Kong who have high blood pressure and are not taking blood pressure medicine. It tests a Bifidobacterium probiotic for 12 weeks.

Age
40 to 65 years old.
Sex
Men and women can join.
Disease stage
Clinic systolic blood pressure of 130 mmHg or higher at the screening visit. People above 165 mmHg cannot join.
Earlier treatment
No blood pressure medicine within the last 4 weeks. No antibiotics or anti-oxidant vitamins within 6 months. No probiotics, omega-3 supplements, rifaximin or steroids now.

Main reasons for not taking part

  • Known diabetes, heart disease, stroke, cancer or chronic kidney disease
  • Known bowel or stomach disorders, such as inflammatory bowel disease or liver cirrhosis
  • Higher risk of infection, for example an organ transplant, HIV or heart valve devices
  • Pregnant, planning pregnancy or breastfeeding
  • Taking part in another clinical or nutrition study in the last 30 days

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Men or women, aged 40-65 years old
  • Chinese residing in Hong Kong
  • Clinic SBP ≥130mmHg according to screening measurement at baseline
  • Untreated or not on antihypertensive medications within 4 weeks
  • Able to provide informed consent

Who cannot take part

  • Currently taking omega-3 fatty acid supplements, probiotics, rifaximin, steroids, and antihypertensive agents within 4 weeks
  • Currently taking antibiotics within 6 months
  • Currently taking anti-oxidant vitamins within 6 months
  • Recent bariatric surgery, hepatic resection, intestinal resection/colectomy, or any surgery within 3 months before the study
  • Intending to participate or have participated in a clinical or nutritional intervention study in the last 30 days before study enrolment
  • Known history of diabetes, coronary artery disease, stroke, peripheral artery disease, malignancy or chronic kidney disease
  • Known history of gastrointestinal disorders including inflammatory bowel disease, irritable bowel syndrome, Helicobacter pylori infection, liver cirrhosis or long-term use of proton pump inhibitors
  • Known increased risk of infection due to endovascular or rheumatic heart disease, endovascular grafts, congenital heart defects, endocarditis, mechanical heart valves, and permanent endovascular devices including permanent (not temporary) hemodialysis catheters, pacemakers, or defibrillators
  • Known secondary causes of hypertension
  • Known allergies to any of the components of Bifidobacterium-based probiotics supplement
  • Identified higher susceptibility to infections caused by immunosuppression, such as a history of organ or hematopoietic stem cell (HSCs) transplant, neutropenia (ANC <500 cells/µl), HIV, and CD4 <200 cells/µl
  • Clinic SBP >165mmHg according to screening measurement at baseline
  • Recent travel to tropical areas within 6 months
  • Women who are pregnant, or intending to become pregnant, or lactation

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 40 and 65 years old?

Where in Hong Kong

  • The University of Hong KongHong Kong, Hong KongContact: Gary Kui-Kai LauNot yet recruiting

About the trial

What the trial wants to find out

The primary objective of this study is to investigate if a Bifidobacterium-based probiotic intervention would reduce clinic systolic BP in untreated middle-aged Chinese men and women with hypertension according to ACC/AHA guidelines (SBP ≥130 mm Hg) after 12 weeks of treatment. The investigators anticipate that this feasibility study will provide rationale to conduct a larger randomized clinical trial and preliminary data to estimate the power/ sample size of a larger RCT.

The group in the trial

  • 30 recruited participants receiving commercially available probiotics supplementsTreatment being tested

    30 community-dwelling, middle-aged Hong Kong Chinese (15 men and 15 women) with hypertension according to ACC/AHA guidelines (SBP ≥130 mm Hg) who are not taking antihypertensive agents and are free of symptomatic cardiovascular or cerebrovascular diseases will be recruited in this study. Participants will be recruited via our outreach promotion program or social media and recruitment posters will be distributed physically or posted online.

    Treatment: Bifidobacterium probiotics supplementation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The Effects of Bifidobacterium-based Probiotics in Reducing Blood Pressure in Middle-aged Chinese With Hypertension: a Single-arm Feasibility Pilot Study
Plain-language title
Tests probiotic bacteria for blood pressure in middle-aged adults with hypertensionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07206303, who can take part
Record updated
31 August 2026